TABLE 4.

Summary of pharmacokinetic parameters obtained with single dose intravenous cαSx1 and cαStx2 administered individually or concomitantlya

Antibody (dose)ParameterCmax (mg/liter)Tmax (h)AUCb (mg · h/ml)t1/2b (hours)CLb (ml/h/kg)Vzb (liters/kg)
cαStx1 (1.0 mg/kg)Mean24.9343.443,788.946157.210.340.06
SD3.5652.642,461.25583.440.150.01
CV (%)14.376.565.053.144.914.2
No. of subjects996666
cαStx1 (3.0 mg/kg)Mean73.2093.978,683.858215.320.410.11
SD21.8213.554,305.828172.850.170.8
CV (%)29.889.449.680.340.771.9
No. of subjects998888
cαStx2 (1.0 mg/kg)Mean25.3023.535,470.119315.960.210.08
SD4.8492.941,894.649165.350.100.03
CV (%)19.283.134.652.348.838.9
No. of subjects886666
cαStx2 (3.0 mg/kg)Mean88.1253.1115,520.314223.680.200.06
SD17.3232.003,825.12534.510.050.02
CV (%)19.764.224.615.423.423.7
No. of subjects999999
  • a Data were analyzed by noncompartmental PK methods.

  • b Due to the lack of a log-linear decay, the slope of the terminal log-linear phase (λz) and parameters dependent on λz, AUC, t1/2, CL, and Vz, could not be estimated for all subjects.